Skip to content

Nasdaq · CIK 0001231457

GNLX GENELUX Corp

Insider trading from SEC Form 4. Last filing 40 d ago. Close $2.56 on Oct 9, 2026, +11% from the 52-week low and -69% from the high.

Last 90 days

Net insider value
-$147k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$147k by 3 insiders
Insiders on file
13
with a Form 4 at this company

Price and insider trades, last year

GNLXOct 9, 2026 · close 2.56

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at GENELUX Corp, scored.

ScoreInsiderValueHoldingsPrice contextFiled
35WeakJoseph Cappello
Chief Technical Officer
sell
$28k
10,257 shares
-3%-
35WeakYong Yu
Chief Scientific Officer
sell
$27k
9,683 shares
-4%-
49ModerateThomas Zindrick
President and CEO
sell
$92k
34,463 shares
-3%-
15WeakJoseph Cappello
Chief Technical Officer
sell
$14k
3,706 shares
-2%+74% from low-39% from high
30WeakJoseph Cappello
VP, Pharmaceutical Development
sell
$14k
4,737 shares
-8%+40% from low-51% from high
30WeakRalph Smalling
Head of Regulatory
sell
$3,676
1,259 shares
-3%+40% from low-51% from high
35WeakYong Yu
VP, Clinical Trial Operations
sell
$16k
5,579 shares
-10%+40% from low-51% from high
45ModerateThomas Zindrick
President and CEO
sell
$31k
10,764 shares
-5%+40% from low-51% from high
30WeakSean Ryder
General Counsel
sell
$13k
4,475 shares
-9%+40% from low-51% from high
30WeakJames L Tyree
director
sell
$8,512
3,460 shares
-7%-
40ModerateJoseph Cappello
VP, Pharmaceutical Development
sell
$15k
6,300 shares
-30%-
35WeakRalph Smalling
Head of Regulatory
sell
$5,873
2,510 shares
-13%-
37WeakLourie S. Zak
Chief Financial Officer
sell
$4,921
2,103 shares
-5%-
56ModerateThomas Zindrick
President and CEO
sell
$33k
14,315 shares
-28%-

Transactions

The last 81 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Aug 31, 2026Yong Yu
Chief Scientific Officer
SOpen-market sale
Common Stock
-9,683$2.75$27k258,68840 d ago
Aug 31, 2026Thomas Zindrick
President and CEO
SOpen-market sale
Common Stock
-34,463$2.67$92k1,226,42740 d ago
Aug 31, 2026Joseph Cappello
Chief Technical Officer
SOpen-market sale
Common Stock
-10,257$2.74$28k318,48040 d ago
Aug 21, 2025Joseph Cappello
Chief Technical Officer
SOpen-market sale
Common Stock
-1,270$3.33$4,225158,496Dec 11, 2025
Aug 21, 2025Joseph Cappello
Chief Technical Officer
SOpen-market sale
Common Stock
-1,463$3.36$4,912157,033Dec 11, 2025
Nov 17, 2025Joseph Cappello
Chief Technical Officer
SOpen-market sale
Common Stock
-973$5.37$5,224156,060Dec 11, 2025
Sep 1, 2025Thomas Zindrick
President and CEO
DDisposition to issuer
Stock Option (Right to Buy)derivative
-925,000--0Sep 3, 2025
Sep 1, 2025Yong Yu
SVP, Clinical Development
DDisposition to issuer
Stock Option (Right to Buy)derivative
-207,652--0Sep 3, 2025
Sep 1, 2025Ralph Smalling
Head of Regulatory
AGrant or award
Common Stock
+10,000$0.00$070,990Sep 3, 2025
Sep 1, 2025Joseph Cappello
Chief Technical Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-16,666--0Sep 3, 2025
Sep 1, 2025Ralph Smalling
Head of Regulatory
DDisposition to issuer
Stock Option (Right to Buy)derivative
-8,333--0Sep 3, 2025
Sep 1, 2025Thomas Zindrick
President and CEO
AGrant or award
Stock Option (Right to Buy)derivative
+925,000--925,000Sep 3, 2025
Sep 1, 2025Joseph Cappello
Chief Technical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+16,666--16,666Sep 3, 2025
Sep 1, 2025Yong Yu
SVP, Clinical Development
AGrant or award
Stock Option (Right to Buy)derivative
+207,652--207,652Sep 3, 2025
Sep 1, 2025Yong Yu
SVP, Clinical Development
DDisposition to issuer
Stock Option (Right to Buy)derivative
-65,000--0Sep 3, 2025
Sep 1, 2025Joseph Cappello
Chief Technical Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-80,000--0Sep 3, 2025
Sep 1, 2025Thomas Zindrick
President and CEO
DDisposition to issuer
Stock Option (Right to Buy)derivative
-157,372--0Sep 3, 2025
Sep 1, 2025Ralph Smalling
Head of Regulatory
AGrant or award
Stock Option (Right to Buy)derivative
+8,333--8,333Sep 3, 2025
Sep 1, 2025Yong Yu
SVP, Clinical Development
AGrant or award
Stock Option (Right to Buy)derivative
+65,000--65,000Sep 3, 2025
Sep 1, 2025Joseph Cappello
Chief Technical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+80,000--80,000Sep 3, 2025
Sep 1, 2025Thomas Zindrick
President and CEO
AGrant or award
Stock Option (Right to Buy)derivative
+157,372--157,372Sep 3, 2025
Sep 1, 2025Joseph Cappello
Chief Technical Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-13,333--0Sep 3, 2025
Sep 1, 2025Thomas Zindrick
President and CEO
DDisposition to issuer
Stock Option (Right to Buy)derivative
-23,568--0Sep 3, 2025
Sep 1, 2025Thomas Zindrick
President and CEO
AGrant or award
Stock Option (Right to Buy)derivative
+23,568--23,568Sep 3, 2025
Sep 1, 2025Joseph Cappello
Chief Technical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+13,333--13,333Sep 3, 2025
Sep 1, 2025Joseph Cappello
Chief Technical Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-65,000--0Sep 3, 2025
Sep 1, 2025Thomas Zindrick
President and CEO
DDisposition to issuer
Stock Option (Right to Buy)derivative
-250,000--0Sep 3, 2025
Sep 1, 2025Thomas Zindrick
President and CEO
AGrant or award
Stock Option (Right to Buy)derivative
+250,000--250,000Sep 3, 2025
Sep 1, 2025Joseph Cappello
Chief Technical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+65,000--65,000Sep 3, 2025
Aug 27, 2025Joseph Cappello
Chief Technical Officer
AGrant or award
Common Stock
+107,500$0.00$0159,766Aug 29, 2025
Aug 27, 2025Ralph Smalling
Head of Regulatory
AGrant or award
Common Stock
+26,230$0.00$060,990Aug 29, 2025
Aug 27, 2025Yong Yu
SVP, Clinical Development
AGrant or award
Common Stock
+101,480$0.00$0150,036Aug 29, 2025
Aug 27, 2025Thomas Zindrick
President and CEO
AGrant or award
Common Stock
+361,200$0.00$0554,161Aug 29, 2025
Aug 27, 2025James L Tyree
director
AGrant or award
Common Stock
+22,283$0.00$068,074Aug 29, 2025
Aug 27, 2025John Thomas
director
AGrant or award
Common Stock
+22,283$0.00$0502,784Aug 29, 2025
Aug 27, 2025Mary Mirabelli
director
AGrant or award
Common Stock
+22,283$0.00$073,284Aug 29, 2025
Aug 27, 2025John W Smither
director
AGrant or award
Common Stock
+22,283$0.00$074,994Aug 29, 2025
Aug 27, 2025John W Smither
director
AGrant or award
Stock Option (Right to Buy)derivative
+28,576$0.00$028,576Aug 29, 2025
Aug 27, 2025James L Tyree
director
AGrant or award
Stock Option (Right to Buy)derivative
+28,576$0.00$028,576Aug 29, 2025
Aug 27, 2025John Thomas
director
AGrant or award
Stock Option (Right to Buy)derivative
+28,576$0.00$028,576Aug 29, 2025
Aug 27, 2025Thomas Zindrick
President and CEO
AGrant or award
Stock Option (Right to Buy)derivative
+478,800$0.00$0478,800Aug 29, 2025
Aug 27, 2025Yong Yu
SVP, Clinical Development
AGrant or award
Stock Option (Right to Buy)derivative
+134,520$0.00$0134,520Aug 29, 2025
Aug 27, 2025Ralph Smalling
Head of Regulatory
AGrant or award
Stock Option (Right to Buy)derivative
+34,770$0.00$034,770Aug 29, 2025
Aug 27, 2025Joseph Cappello
Chief Technical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+142,500$0.00$0142,500Aug 29, 2025
Aug 27, 2025Mary Mirabelli
director
AGrant or award
Stock Option (Right to Buy)derivative
+28,576$0.00$028,576Aug 29, 2025
Jul 1, 2025Eric Groen
General Counsel & Secretary
AGrant or award
Stock Option (Right to Buy)derivative
+270,000$0.00$0270,000Jul 2, 2025
Jun 6, 2025John Thomas
director
GGift
Common Stock
-25,000$0.00$0480,501Jun 24, 2025
May 12, 2025Thomas Zindrick
President and CEO
SOpen-market sale
Common Stock
-10,764$2.92$31k191,447May 13, 2025
May 12, 2025Sean Ryder
General Counsel
SOpen-market sale
Common Stock
-4,475$2.92$13k47,621May 13, 2025
May 12, 2025Yong Yu
VP, Clinical Trial Operations
SOpen-market sale
Common Stock
-5,579$2.92$16k47,640May 13, 2025
May 12, 2025Ralph Smalling
Head of Regulatory
SOpen-market sale
Common Stock
-1,259$2.92$3,67634,760May 13, 2025
May 12, 2025Joseph Cappello
VP, Pharmaceutical Development
SOpen-market sale
Common Stock
-4,737$2.92$14k52,266May 13, 2025
Mar 14, 2025Joseph Cappello
VP, Pharmaceutical Development
AGrant or award
Common Stock
+13,350$0.00$057,003Apr 17, 2025
Mar 14, 2025Thomas Zindrick
President and CEO
AGrant or award
Common Stock
+30,339$0.00$0202,211Apr 17, 2025
Mar 14, 2025Sean Ryder
General Counsel
AGrant or award
Common Stock
+10,708$0.00$052,096Apr 17, 2025
Mar 14, 2025Yong Yu
VP, Clinical Trial Operations
AGrant or award
Common Stock
+13,350$0.00$053,219Apr 17, 2025
Mar 14, 2025Ralph Smalling
Head of Regulatory
AGrant or award
Common Stock
+4,172$0.00$036,019Apr 17, 2025
Jan 31, 2025Matthew Pulisic
Chief Financial Officer
AGrant or award
Stock Option (right to buy)derivative
+275,000$0.00$0275,000Feb 3, 2025
Aug 1, 2024John Thomas
director
AGrant or award
Stock Option Right to Buy)derivative
+50,469$0.00$050,469Dec 31, 2024
Aug 1, 2024Mary Mirabelli
director
AGrant or award
Stock Option Right to Buy)derivative
+50,469$0.00$050,469Dec 31, 2024
Aug 1, 2024John W Smither
director
AGrant or award
Stock Option Right to Buy)derivative
+50,469$0.00$050,469Dec 31, 2024
Aug 1, 2024James L Tyree
director
AGrant or award
Stock Option Right to Buy)derivative
+50,469$0.00$050,469Dec 31, 2024
Dec 30, 2024James L Tyree
director
SOpen-market sale
Common Stock
-3,460$2.46$8,51245,791Dec 30, 2024
Dec 18, 2024Lourie S. Zak
Chief Financial Officer
AGrant or award
Common Stock
+41,650$0.00$082,452Dec 20, 2024
Dec 18, 2024Joseph Cappello
VP, Pharmaceutical Development
AGrant or award
Common Stock
+29,000$0.00$043,653Dec 20, 2024
Dec 18, 2024Thomas Zindrick
President and CEO
AGrant or award
Common Stock
+134,500$0.00$0171,872Dec 20, 2024
Dec 18, 2024Ralph Smalling
Head of Regulatory
AGrant or award
Common Stock
+15,525$0.00$031,847Dec 20, 2024
Dec 18, 2024Sean Ryder
General Counsel
AGrant or award
Common Stock
+22,000$0.00$041,388Dec 20, 2024
Dec 18, 2024Yong Yu
VP, Clinical Trial Operations
AGrant or award
Common Stock
+29,000$0.00$039,869Dec 20, 2024
Dec 18, 2024Sean Ryder
General Counsel
AGrant or award
Stock Option (right to buy)derivative
+30,000$0.00$030,000Dec 20, 2024
Dec 18, 2024Yong Yu
VP, Clinical Trial Operations
AGrant or award
Stock Option (right to buy)derivative
+39,000$0.00$039,000Dec 20, 2024
Dec 18, 2024Ralph Smalling
Head of Regulatory
AGrant or award
Stock Option (right to buy)derivative
+21,100$0.00$021,100Dec 20, 2024
Dec 18, 2024Joseph Cappello
VP, Pharmaceutical Development
AGrant or award
Stock Option (right to buy)derivative
+39,000$0.00$039,000Dec 20, 2024
Dec 18, 2024Lourie S. Zak
Chief Financial Officer
AGrant or award
Stock Option (right to buy)derivative
+56,525$0.00$056,525Dec 20, 2024
Dec 18, 2024Thomas Zindrick
President and CEO
AGrant or award
Stock Option (right to buy)derivative
+183,000$0.00$0183,000Dec 20, 2024
Dec 16, 2024Joseph Cappello
VP, Pharmaceutical Development
SOpen-market sale
Common Stock
-6,300$2.34$15k14,653Dec 18, 2024
Dec 16, 2024Ralph Smalling
Head of Regulatory
SOpen-market sale
Common Stock
-2,510$2.34$5,87316,322Dec 18, 2024
Dec 16, 2024Lourie S. Zak
Chief Financial Officer
SOpen-market sale
Common Stock
-2,103$2.34$4,92140,802Dec 18, 2024
Dec 16, 2024Thomas Zindrick
President and CEO
SOpen-market sale
Common Stock
-14,315$2.34$33k37,372Dec 18, 2024
Oct 18, 2024Paul Scigalla
Chief Medical Officer
AGrant or award
Stock Option (right to buy)derivative
+16,666$0.00$016,666Oct 21, 2024
Oct 18, 2024Paul Scigalla
Chief Medical Officer
AGrant or award
Stock Option (right to buy)derivative
+16,666$0.00$016,666Oct 21, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

GNLX insider trading: GENELUX Corp | InsiderTell